{"id":"https://openalex.org/W2020249147","doi":"https://doi.org/10.1586/erc.10.62","title":"Contemporary management of patients with Type 2 diabetes","display_name":"Contemporary management of patients with Type 2 diabetes","alternate_titles":[],"publication_year":2010,"publication_date":"2010-06-01","ids":{"openalex":"https://openalex.org/W2020249147","doi":"https://doi.org/10.1586/erc.10.62","mag":"2020249147","pmid":"https://pubmed.ncbi.nlm.nih.gov/20528633"},"language":"en","primary_location":{"id":"doi:10.1586/erc.10.62","doi":"https://doi.org/10.1586/erc.10.62","is_oa":false,"landing_page_url":"https://doi.org/10.1586/erc.10.62","pdf_url":null,"source":{"id":"https://openalex.org/S108504264","display_name":"Expert Review of Cardiovascular Therapy","issn_l":"1477-9072","issn":["1477-9072","1744-8344"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Cardiovascular Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2020249147"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113688884","display_name":"Carrie McAdam-Marx","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Carrie McAdam-Marx","raw_affiliation_strings":["University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA. carrie.mcadam-marx@pharm.utah.edu","University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA. carrie.mcadam-marx@pharm.utah.edu","institution_ids":["https://openalex.org/I223532165"]},{"raw_affiliation_string":"University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018758989","display_name":"Julia A. Gaebler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Julia A Gaebler","raw_affiliation_strings":["Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA; Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA","Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA; Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA","institution_ids":[]},{"raw_affiliation_string":"Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045032519","display_name":"Brandon Kyle Bellows","orcid":"https://orcid.org/0000-0003-1395-6047","observed_orcids":["https://orcid.org/0000-0003-1395-6047"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Brandon K Bellows","raw_affiliation_strings":["University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA; University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA; University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","institution_ids":["https://openalex.org/I223532165"]},{"raw_affiliation_string":"University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040963321","display_name":"Diana I Brixner","orcid":"https://orcid.org/0000-0001-6637-6359","observed_orcids":["https://orcid.org/0000-0001-6637-6359"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Diana I Brixner","raw_affiliation_strings":["University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA; University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA; University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","institution_ids":["https://openalex.org/I223532165"]},{"raw_affiliation_string":"University of Utah Pharmacotherapy Outcomes Research Center, 421 Wakara Way, Room 208, Salt Lake City, UT 84108, USA","institution_ids":["https://openalex.org/I223532165"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1783,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.564761,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":"8","issue":"6","first_page":"767","last_page":"770"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9890000224113464},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9279999732971191},{"id":"https://openalex.org/keywords/systolic-blood-pressure","display_name":"systolic blood pressure","score":0.9769999980926514},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.6909999847412109},{"id":"https://openalex.org/keywords/antidiabetic-therapy","display_name":"antidiabetic therapy","score":0.6190000176429749},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.6980000138282776},{"id":"https://openalex.org/keywords/hypoglycemia-risk","display_name":"hypoglycemia risk","score":0.7509999871253967},{"id":"https://openalex.org/keywords/body-weight","display_name":"body weight","score":0.7919999957084656}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9641097187995911},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9123878479003906},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.8008082509040833},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.7414846420288086},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.6922518014907837},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6247872710227966},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5955469608306885},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.5302241444587708},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.4571535289287567},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.45647862553596497},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.39510753750801086},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.38027966022491455}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1586/erc.10.62","doi":"https://doi.org/10.1586/erc.10.62","is_oa":false,"landing_page_url":"https://doi.org/10.1586/erc.10.62","pdf_url":null,"source":{"id":"https://openalex.org/S108504264","display_name":"Expert Review of Cardiovascular Therapy","issn_l":"1477-9072","issn":["1477-9072","1744-8344"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Cardiovascular Therapy","raw_type":"journal-article"},{"id":"pmid:20528633","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20528633","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of cardiovascular therapy","raw_type":"Comment"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W91242618","https://openalex.org/W100598291","https://openalex.org/W172609984","https://openalex.org/W1984740259","https://openalex.org/W1986085856","https://openalex.org/W1999843320","https://openalex.org/W2000976083","https://openalex.org/W2016622896","https://openalex.org/W2023462541","https://openalex.org/W2038335142","https://openalex.org/W2046645679","https://openalex.org/W2053348407","https://openalex.org/W2059555444","https://openalex.org/W2070710390","https://openalex.org/W2082724449","https://openalex.org/W2093738306","https://openalex.org/W2097482222","https://openalex.org/W2098459806","https://openalex.org/W2103525547","https://openalex.org/W2108646121","https://openalex.org/W2111765225","https://openalex.org/W2129578585","https://openalex.org/W2129730863","https://openalex.org/W2150423648","https://openalex.org/W2158666727","https://openalex.org/W2160001758","https://openalex.org/W2166494634","https://openalex.org/W2509949587","https://openalex.org/W2596624061","https://openalex.org/W4246288537"],"related_works":["https://openalex.org/W3038103931","https://openalex.org/W1999843320","https://openalex.org/W2009551415","https://openalex.org/W2111765225","https://openalex.org/W2791619799","https://openalex.org/W2522021563","https://openalex.org/W1973442218","https://openalex.org/W2007217090"],"abstract_inverted_index":{"EVALUATION":[0],"OF:":[1],"Okerson":[2,96],"T,":[3],"Yan":[4],"P,":[5],"Stonehouse":[6],"A,":[7],"Brodows":[8],"R.":[9],"Effects":[10],"of":[11,65,91],"exenatide":[12],"on":[13,71],"systolic":[14,104,117],"blood":[15,52,105,118],"pressure":[16,106],"in":[17,55,81,103,107,113],"subjects":[18],"with":[19,57,61,110,115],"Type":[20,29,58,134],"2":[21,30,59,135],"diabetes.":[22],"Am.":[23],"J.":[24],"Hypertens.":[25],"23(3),":[26],"334-339":[27],"(2010).":[28],"diabetes":[31,60,136],"is":[32],"often":[33],"accompanied":[34],"by":[35],"other":[36,140],"comorbidities":[37],"that":[38,75,125],"similarly":[39],"contribute":[40],"to":[41],"cardiovascular":[42,84,141],"risk.":[43],"New":[44],"antidiabetics":[45],"including":[46],"glucagon-like":[47,126],"peptide-1":[48,127],"agonists":[49,128],"have":[50],"demonstrated":[51],"glucose":[53],"control":[54],"patients":[56,108,114],"a":[62,68,87,100],"low":[63],"risk":[64,142],"hypoglycemia":[66],"and":[67],"favorable":[69],"impact":[70],"bodyweight.":[72],"Evidence":[73],"suggests":[74],"these":[76],"agents":[77],"may":[78],"convey":[79],"benefit":[80,131],"managing":[82,133,139],"additional":[83],"risks.":[85],"In":[86],"recent":[88],"pooled":[89],"analysis":[90],"randomized":[92],"controlled":[93],"trial":[94],"data,":[95],"et":[97],"al.":[98],"identified":[99],"significant":[101],"reduction":[102],"treated":[109],"exenatide,":[111],"particularly":[112],"elevated":[116],"pressure.":[119],"This":[120],"study":[121],"provides":[122],"further":[123],"evidence":[124],"confer":[129],"therapeutic":[130],"for":[132],"while":[137],"also":[138],"factors.":[143]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2020249147","counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
